🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

Recruitingn/aAges 40 Years - anyAllSanofi
NCT07612878 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD. Secondary objectives are to determine whether treatment with dupilumab reduces moderate and/or severe COPD exacerbations; to determine the impact of treatment on lung function in COPD participants; to determine whether treatment with dupilumab improves the quality of life in COPD participants; and to describe safety of dupilumab among COPD participants. The external control cohort will include participants with COPD from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. In addition, chest images will be collected and banked for future research projects and consented participants will perform home spi

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * COPD patients who are newly referred to start dupilumab treatment * Age ≥ 40 years * Standard of care spirometry performed concurrently with the baseline visit or within 90 days prior to the baseline visit Exclusion Criteria: * Patients who have contraindication to dupilumab according to the United States Prescribing Information (USPI) * Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, or other comorbidities that can predictably prevent the patient from completing the schedule of assessments * Patients currently participating in any interventional clinical trial The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
💊

What it tests

  • Cohort 1: Dupilumab
  • Cohort 2: usual care only
📍

Where

7 sites
IU Health Pulmonology & Critical Care Medicine
Indianapolis, United States
University of Kansas
Lawrence, United States
Duke
Durham, United States
Ohio State University
Columbus, United States
The Respire Institute
Houston, United States
Activian Clinical Research
Kingwood, United States
The Lung & Sleep Institute of North Texas
North Richland Hills, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy